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ABSTRACT
Supramolecular NanoStamping is a novel printing method for exploiting the
supramolecular interactions between organic and biological molecules. This technology
is advantageous because of the ability to transfer a massive amount of chemical and
spatial information, its high resolution, the growth of masters used multiple times and
the versatility of initial master fabrication. The technology may be used to make DNA
microarrays which are an essential tool to genomic research assisting in gene expression
and genotyping.
This paper explores the potential of bring Supramolecular NanoStamping technology to
the microarray market. An in depth analysis of the current patent landscape of DNA
microarrays is conducted to recognize the various competitors and the coverage of their
patents. In addition, a better understanding of the landscape was achieved by assessing
the major litigation that has occurred in the field. By engaging in a thorough
intellectual property analysis, the commercialization potential of Supramolecular
NanoStamping technology was realized through a licensing model.
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INTRODUCTION
In today's scientific world of biology, there is an overwhelming amount of genetic
information that is being gathered as the human genome is sequenced. As important as
it is to collect all of this knowledge, the staggering amount of data is not useful in
making important discoveries unless it can be carefully deciphered into meaningful data
that may be interpreted. Therefore, in this is technological age, DNA microarrays are
indispensable tools for sorting through all the information to make an impact on
practical applications.
DNA microarrays are able to conduct testing for experiments such as gene expression
and genotyping. By determining gene expression, the DNA sequences, a gene's coded
information, are transformed into the parallel structures and functions of a cell that they
dictate. Treatments for and the developmental stages of diseases can then be studied
from this information. DNA microarrays can also be used for genotyping which studies
an individual's genotype, their genetic constitution, to determine if there are any
dangerous genetic mutations that may cause disease.
As revolutionary as DNA microarrays could make the field of genetics and biology, the
technology is still extremely expensive and not widely available for use in industries
outside of pure research like healthcare. If the tools could be manufactured at a fraction
lof the current cost, then a variety of applications could utilize the technology to combat
diseases from many different angles. Patients could conduct in-home diagnostics by
determining tihe exact strain of cold or flu that they have to match it with the exact
medicine to combat it. Researchers could study single-nucleotide polymorphisms
(SNPs), variations of a single nucleotide base in the DNA sequence, that occur every
couple hundred bases to determine their effects. DNA microarray technology has the
potential to revolutionize the scientific community, but new technological
advancements will need to be made in order to make the technology a commercial
success.
TECHNOLOGY
Goals
The major goal of Supramolecular NanoStamping is to achieve nano-scale resolution
contact printing of bio-chemically complex patterns. In order to achieve that goal, the
process must be carefully crafted to avoid mechanical forces, high temperatures and
etching chemicals which would damage the organic molecules. Nature has created the
perfect solution through DNA/RNA information transfer. This printing method has
many key capabilities that make it the best. It is able to be carried out at room
temperature and in a liquid environment as it occurs in the body. In addition, an
enormous amount of information is transferred with nanometer scale resolution through
the process. Supramolecular NanoStamping utilizes self-assembly and reversible van
der Waals bonds to replicate this complex process.
Methodology
The novel printing method is used for printing organic bio-molecules using the
supramolecular interactions that are present between molecules. To begin with, the first
initial master slide must be fabricated. This slide may be fabricated using one of any of
the currently available techniques, such as photolithography, electron beam (E-beam)
lithography or spotting. In spotting, a machines spotter specifically made for making
microarrays is used to create the master. Textured substrates are soaked in a single-
stranded DNA solution to create a monolayer over the surface and then carefully printed
so that only the raised parts make contact in E-beam lithography. On the other hand,
the photolithography process uses ultraviolet light shined onto a microarray with a mask
so that the unprotected sections activities linker molecules to couple with DNA.
Therefore, in theory, any microarray can be used as a master since the Supramolecular
NanoStamping principle does not rely on the DNA binding to the substrate but rather
with its complement. Although any one of these tradition methods may be used, the
process works best when the initial master is packed in such a way that it is sufficiently
dense and resembles a self-assembled monolayer where the DNA is standing as close to
upright as possible.
After the initial master slide is produced, the substrate should be immersed in a solution
containing the DNA complements of the single-stranded DNA (ssDNA) on the master.
Like the DNA on the substrate, the complementary DNA (cDNA) is composed of a
DNA backbone connected to a flexible linker with an attachment group on the end used
to bind to a substrate. Schematics of the single-stranded DNA on the substrate and its
complements can be seen in Figures 1A and 1B, respectively. In the solution, the
complementary pairs will hybridize with the corresponding molecules on the master.
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After removing the substrate from the solution, its DNA is in the double helix form with
two single strands hybridized together and attachment groups on each end. A secondary
substrate is gently brought into contact with the master substrate so that the free
attachment group can adhere to the new substrate. After the surface approach is
complete, the entire system is heated in order to de-hybridize the DNA so that the two
substrates may be separated (Yu, 2005). A schematic of the entire process can be seen
is Figure 2 below.
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Step 2:
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Figure 2: Schematics of the Supramolecular NanoStamping process:
1) Hybridization of DNA complements in solution, 2) Surface
approach of secondary substrate with master and 3) De-
hybridization of DNA by heating to separate substrates.
Following the red arrow, the process may be repeated again.
From the Supramolecular NanoStamping process, a secondary substrate (a daughter
master) is created from the initial master. The daughter represents a replica of the
master with the exception that the DNA is the complementary strand to the master. In
terms of spatial and chemical information, everything is preserved on the daughter
master. If the process was carried out again, on the daughter master rather than the
000
initial master, then the grand-daughter master created would be an exact replica of the
initial master. After only two iterations of Supramolecular NanoStamping, an exact
copy of the first master can be fabricated.
Substrates
The Supramolecular NanoStamping process was first shown to work on a gold (Au)
substrate. For this substrate, thiols (-SH groups) were attached to the ends of the DNA
backbone for their strong adherence to gold. Although gold material provides a
substrate for high resolution, it is problematic for several reasons including its poor
mechanical properties and high costs. Therefore, once the concept was proven to work,
a new substrate was sought to alleviate these issues (Yu, 2005).
In addition to gold, the method has also been shown to work on poly (methyl
methacrylate) (PMMA) substrates. PMMA material provides several advantages that
gold does not. To begin with, the cost of PMMA is only a small fraction of the cost of
gold of mica. Furthermore, PMMA has several intrinsic properties that make it a good
candidate for bio-array systems. The material is optically transparent, electrically
insulting and flexible and mechanically robust at room temperature. In addition, it is
also relatively stable and can be washed in water without deteriorating. Supramolecular
NanoStamping with PMMA substrates has been able to retain the same level of
resolution and coverage as with gold substrates (Yu, 2005). Although performing the
process on PMMA substrates represents an important advancement in developing the
binding chemistry between the DNA and new substrates, other materials are still being
investigated. Currently, research is being conducted into using polydimethylsiloxane
(PDMS) substrates. By achieving adherence with this surface chemistry, an important
step will be taken since silicon substrates are often used for DNA microarrays.
Advantages
Supramolecular NanoStamping holds many advantages over other DNA microarray
fabrication methods such as spotting or photolithography. First, the growth and
multiplication of masters is enabled as they can be used and over again to create new
masters. Current research establishes that the masters may be used up to seven to eight
times without losing a significant amount of resolution or coverage. Second, the
extreme versatility of the initial master fabrication is crucial as it allows this process to
be used with virtually any microarray or master. Third, a high resolution of less than
forty nanometers can be achieved for high clarity and precision. Finally, the process
provides the potential for the transfer of a massive amount of both spatial information
about the DNA pattern and chemical information about the DNA sequence (Yu, 2005).
Supramolecular NanoStamping technology holds much promise for future biological
applications.
APPLICATIONS
Potential
Several applications utilizing the diversity of possible attachment groups can be derived
from this technology. The DNA on the substrate can be modified with both organic and
inorganic materials by assembling along the printed pattern of strands. This
modification can be made is two ways. In one method, the negative charge of the DNA
backbone can be employed, especially in the case of assembling metals. If a master
substrate with a DNA pattern printed onto it is immersed in a solution of metallic
nanoparticles, the nanoparticles will automatically assemble onto the DNA pattern
because metal is usually positively charged in an aqueous environment. The downside
to this assembly process though is that it is not sequence specific.
In another method, the sequence specific binding is exploited. The target material,
whether organic or inorganic, can be attached to the DNA complements of the single-
stranded DNA on the substrate pattern. Then, the material can then be easily attached
to the substrate when the DNA complements hybridize together. A key advantage to
this process is that many different materials can be attached onto the substrate at the
same time to fabricate complex devices. Since it is dependent on the specific binding
and hybridization between a pair of single-stranded DNA strands, a solution with
different sequence strands (each connected to a unique attachment group) can be used to
match a DNA pattern composed of the different sequence complementary strands.
Currently, some complex nano-devices are manufactured in a slow manner and at high
costs. However, with this new process, nano-devices like optical biosensors, single-
electron transistors, metallic wires and micro- and nano-fluidics channels can be
produced efficiently and economically.
Target
Despite the potential to revolutionize the production of several different nano-devices,
the target application for Supramolecular NanoStamping technology is as a new
synthesis method for DNA microarrays, also known as gene chips or DNA chips. A
variety of fabrication methods are currently available to make DNA microarrays (see
picture in Figure 3) including spotting and photolithography. However, each of these
methods has its disadvantages that Supramolecular NanoStamping can overcome such
as being able to print DNA strands of various lengths, short or long on a relative scale.
Figure 3: Photograph of a fluorescently tagged DNA microarray.
Image courtesy of: http://www2.niaid.nih.gov/newsroom/focuson/tb02/microarrays.htm
DNA microarrays are composed of tens of thousands of unique, microscopic DNA
spots attached to a substrate forming an ordered array. The spots are DNA segments or
probes of different sequences and are attached to substrates like glass or silicon chips.
Fluorescently tagged biological samples are run over a microarray to see where the
sample attaches to the substrate. Information about the sample can be obtained and the
expression levels for many genes may be evaluated simultaneously. DNA microarrays
can provide knowledge that leads to finding polymorphisms for drug discovery
(measuring the effect of a specific drug on a particular set of genes) and
pharmacogenomics or monitoring gene expression for identifying genetic diseases
(Liebeschuetz, 2003).
INTELLECTUAL PROPERTY
Competing Technologies and Patents
AFFYMETRIX
The industry's past and current leading company is Affymetrix of Santa Clara,
California since their inception in 1991 (Bouchie, 2002). They were the first to
commercialize their technology and push significant volume out to customers due to the
high production rate of their Genechip@ (as seen in Figures 4A and 4B) that they were
able to achieve, up to 10,000 chips a month initially. A significant advantage to
Affymetrix's DNA microarray is their ability to make a high density array, higher than
any other commercial technology. The Genechip@ is covered by patent number US
5,445,934 Array of oligonucleotides on a solid substrate issued in 1995. The first
independent claim of this patent recites "A substrate with a surface comprising 103 or
more groups of oligonucleotides with different, known sequences covalently attached to
the surface in discrete known regions, said 10' or more groups of oligonucleotides
occupying a total area of less than 1 cm2 on said substrate, said groups of
oligonucleotides having different nucleotide sequences."
This patent crucial to Affymetrix's portfolio was filed in 1989 and the first of a genre of
patents on the microarray that would soon follow. By being the leader of the pack,
Affymetrix had the advantage of setting the precedent for the field but the difficulty of
presenting a new and unfamiliar type of invention to the United Patent and Trademark
Office requiring a long dialogue of communication for clarification before it would be
allowed (Liebeschuetz, 2003).
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The company now holds nearly 300 patents with a continuous flow of pending patent
applications. It has not been an easy road for the company though as they incurred
significant initial losses of nearly $67 million until they were able to reverse their
fortune in 1997. More recently though, Affymetrix has been profitable after a positive
earning of $10 million that year (including $15 million in government research grants
and contracts).
Due to its prominent position in the market, Affymetrix receives a great amount of
attention and scrutiny-and it's not always postitive. Their executives believe that this
market is just like any business and the company has the right and responsibility to its
investors to profit from its proprietary technology. From this mentality, many in the
industry consider the company to be a bully trying to scare off others from trying to get
into the market. The dislike towards them is magnified by the perception that their
corporate philosophy is to aggressively defend their technology and monopolize the
field by demanding high licensing fees for competitors to enter the market. In addition
to filing patents on all technologies related to their Genechip@, they have also asserted
those patents and threatened litigation. The extremely sensitive nature of the research
radically touches a nerve in the scientific community. It's not just about a company
dominating the electronics industry to build the fastest computer, but about a company
owning the DNA microarray industry which may be the key tools for curing diseases
and understanding the biological world (Alexander, 2000). The way this market shapes
may determine how scientists even conduct their research which means that
Affymetrix's actions have far reaching implications.
The proprietary technology that Affymetrix has patented is on its photolithography
technique of producing DNA microarrays. This method combines photolithographic
practices developed for the semiconductor industry with combinatorial chemistry. To
begin with, a mask over the substrate, typically a silicon wafer or glass, is used to create
a specific pattern for the microarray. Then, an ultraviolet light is shined on the substrate
so that the linker molecules in the open regions of the mask are unprotected so that they
can be coupled with DNA strands while the closed regions remain protected. Next, the
surface is flushed with a DNA solution of a specific base (adenine (A), thymine (T),
guanine (G) or cytosine (C)) that will attaches to molecules on the substrate. The
process is then repeated three more times, once for each base, until the entire surface is
covered. After the first layer of mers is laid down, the process is continually done until
a DNA strand of 25 mers is built. With four bases for each of the 25 layers, this process
takes 100 steps to complete and the final product with more than 400,000 probes is
schematically shown in Figure 5 below (which also includes a drawing of the actual
chip size, 1.28cm by 1.28 cm).
1.28 cm
1.28 cm
Actual size of
GeneChip" array
I
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500,000 locations on each GeneChip" array
Actual strand = 25 base pairs
Figure 5: Schematic of the photolithography technique used by
Affymetrix to create its GeneChip@
Image courtesy of: http://keck.med.yale.edu/affymetrix/technology.htm
This technology is protected by Affymetrix's pioneer patent, US 5,445,934, which
describes the photolithography method of making DNA microarrays and the apparatus
required for production. In addition, US 6,040,193 Combinatorial strategies for
polymer synthesis issued in 2000 (a continuation of US 5,677,195 issued in 1997)
r
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and US 5,744,305 Arrays of materials attached to a substrate issued in 1998 also cover
their chemical synthesis method for manufacturing DNA microarrays. US 6,040,193
focus on the methodology while US 5,744,305 is a device patent. The first independent
claim of the latter recites "An array of oligonucleotides, the array comprising: a planar,
non-porous solid support having at least a first surface; and a plurality of different
oligonucleotides attached to the first surface of the solid support at a density exceeding
400 different oligonucleotides/cm2 , wherein each of the different oligonucleotides is
attached to the surface of the solid support in a different predefined region, has a
different determinable sequences, and is at least 4 nucleotides in length." Analyzing the
language of the claim is imperative to understanding the scope that the patent covers. In
this particular case, competitors have been able to circumvent the patent by developing
arrays made of porous substrates instead of non-porous ones. For a device to
infringement a patent, every element of the device claimed in the patent must be present
therefore porous substrates are valid.
A disadvantage of Affymetrix's method is that a tradeoff between efficiency and quality
must be made, the more efficiently the process is completed, the poorer the quality of
the resulting microarray. However, this photolithography technique is more efficient
than the base-by-base technique of in situ oligonucleotide synthesis used by its
competitors. Despite the limiting of its technology, Affymetrix was still the first
company to get their product out to the market. Therefore, they can maintain a hold on
their dominant position because of a large patent portfolio and customer loyalty
resulting from reluctance to change suppliers.
AGILENT TECHNOLOGIES
Agilent Technologies is another company that synthesizes DNA microarrays (seen
below in Figure 6) with significant market share. Their technology for fabrication is
completely different and mimics ink-jet printing. This method, called in situ
oligonucleotide synthesis, is made under the name of SurePrint@ and combines printer
technology with standard phosphoamidite chemistry. Instead of using red-blue-green
sequences in this ink-jet-like printing method, different "dot" chemistries are used as
the possibilities to choose from. Each dot is a different sequence of single-stranded
DNA to be attached to the substrate. In this method, 60-mer DNA strands are printed
onto a glass slide base by base. Since the oligonucleotide probes are synthesized
directly on the array one base at a time, there is a high level of precision exhibited by
this technique.
Figure 6: Photograph of DNA microarrays manufactured
by Agilent Technologies
Image courtesy of:
http://www.usc.edu/schools/medicine/research/institutes/igm/content/microarray/instruments.htm
A drawback to this method though is that it is limited by the volume of liquid that must
be deposited to transfer the probes onto the slide. This means that SurePrint@ can only
be used to fabricate low density arrays. In addition, a slow production time results in
inefficiency and high costs. However, in situ oligonucleotide synthesis results in a high
quality array that provides a great amount of information with very few defects.
HYSEQ
Sequencing DNA by hybridization ("SBH") is the key technology that makes Hyseq of
Sunnyvale, California another important player in the DNA microarray market. This
technique uses DNA microarrays in combination with separate oligonucleotide probes,
between 11-20 nucleotides in length, whose sequence is known either to identify or
completely sequence genes of interest. In this method, the oligonucleotide probes are
hybridized onto the target nucleic acid sequence where the complementary probe
sequences are overlapping in sequences. This enables the identification of the target
nucleic acid and accurate DNA sequencing due to the ability to discriminate perfect
sequence hybrids from hybrids with a single nucleotide mismatch (Rouse, 2003).
Hyseq has three crucial patents in its portfolio that protect its core technology and
method: US 5,202,231 Method of sequencing of genomes by hybridization of
oligonucleotide probes in 1993 and US 5,525,464 Method of sequencing by
hybridization of oligonucleotide probes and its continuation US 5,695,940 in 1996 and
1997, respectively.
OXFORD GENE TECHNOLOGY
Another company that should also be mentioned is Oxford Gene Technology of Oxford,
United Kingdom. This company was founded by Edwin Southern, inventor of the
Southern Blot which is used in molecular biology to transfer DNA molecules onto in an
agarose gel electrophoresis for the purpose of detecting specific DNA sequence
fragments. Oxford Gene Technology maintains several patents on methods for
analyzing and making DNA microarrays including US 5,700,637 Apparatus and
method for analyzing polynucleotide sequences and method of generating
oligonucleotide arrays and US 6,054,270 Analyzing polynucleotide sequences.
OTHER COMPANIES
In addition, there are also several other companies who have played a crucial role in
shaping the DNA microarray market. Incyte Pharmaceuticals and Applied Biosystems
have also developed and manufactured chips as seen in Figures 7A and 7B,
respectively.
Figure 7A: Incyte's DNA Figure 7B: Applied Biosystems's
microarray DNA microarray
Image courtesy of:
http://www.devicelink.com/ivdt/archive/
99/01/008.html
Image courtesy of:
http://www.imgm.de/whole_genome_
microarrays.php
It's not just specialized biotech companies in the DNA microarray array market though.
Major companies, such as 3M, Motorola, Corning and Hitachi, are also developing their
own systems. The companies can play up their size and partner with smaller startups,
like Rosetta Inpharmatics, Hyseq, Nanogen and Caliper Technologies, to help
commercialize their technologies. In general, there is a lot of potential in the entire
market for companies to partner together and cooperate to develop new technology.
However, due to the competitive nature of the developing microarray industry, some
companies have begun to stray away from the market and apply their technologies to
other areas. For example, in May of 2002, Nanogen refocused its corporate strategy
and began applying its microfluidics technology to the development of diagnostics
rather than for making devices for gene expression profiling (Bouchie, 2002). Corning,
who entered the game later than the others, has also decided to halt its efforts in the
field citing unfavorable market conditions. The companies named above are only some
of the many companies that are attempting to commercialize the synthesis of DNA
microarrays. There still remains a lot of competition in the industry from these other
companies and none can yet be discounted for being the next major player.
Litigation
AFFYMETRIX AND HYSEQ
In order to fully understand the intellectual property patent landscape of DNA
microarray technology, it is imperative to not only study the competing technologies
and various patents covering those technologies but also the litigation that has occurred
over the lifetime of the market. By carefully scrutinizing the patents that have been
litigated in the field, a better knowledge of the important issues that play a pivotal role
in a company's proprietary technology can be obtained. Furthermore, this step is even
more crucial for DNA microarray synthesis processes because of the strong reliance on
patents for company survival in the industry. All of the technology is closely tied to
each other causing companies to continually step on each other's patents. As a result,
companies must result to asserting their patents over each other to remain dominant or
settle for engaging in cross licensing agreements.
It is no surprise that in all of the major cases litigated over the synthesis of DNA
microarray technology, Affymetrix has been involved as one of the parties. The two
major suits that began the slew of litigation in the synthesis of DNA microarrays were
between Affymetrix and Hyseq and Affymetrix and Incyte. In March 1997, Hyseq sued
Affymetrix in the Northern District Court of California alleging that the company
infringed its sequencing DNA by hybridization ("SBH") patents, US 5,202,231 and US
5,525,464 (Sharrott, 2006). A series of four parallel lawsuits between the companies
followed starting with Affymetrix's countersuit against Hyseq in September of 1998
where they asserted US 5,445,934 and claimed Hyseq infringed by developing
microarrays with densities greater than 400 polynucleotides per square centimeter. For
four years, litigation continued until January 2001 when the Court issued a Markman
ruling, which defines the disputed patent claim terminology, in favor of Affymetrix who
asserted a position of non-infringement (Rouse, 2003).
The pending litigation was finally settled in October of that year when both companies
were able to acknowledge that all the patents in dispute were valid. The settlement set
up a cross-licensing agreement between the parties where Affymetrix granted Hyseq an
assortment of licenses to its pertinent microarray technology while Hyseq granted
Affymetrix a 10% ownership of Callida Genomics, a new subsidiary of the company
established as the assignee of all Hyseq's sequencing DNA by hybridization patents. In
addition to the cross licensing, the two companies also started a partnership to
synthesize DNA microarrays by using both Affymetrix's GenChip@ and Hyseq's
sequencing DNA by hybridization technologies. The research is conducted by a new
subsidiary of Hyseq's Callida Genomics, N-Mer, which Affymetrix may have majority
interest in if they wish to in the future (Sharrott, 2006).
Taking a retrospective look back on the two company's patents involved in the
litigation, it is possible to study how the litigation could have been prevented.
Affymetrix's GeneChip@ technology patents focus on a method of how to manufacture
and make microarrays, while Hyseq's sequencing DNA by hybridization technology
patents focuses on the application and use of microarrays. Therefore, if the two
companies had strategized to play on the strengths of their respective technologies, they
may have been able to work together to develop a collaboration and cross-licensing
agreement without having to spend the large amount of money on litigation that they
did. By anticipating the litigation before it happened and realizing the potential that a
collaboration between the two may have, the companies could have spent the money
and time it had to put into the cost of the suits into developing its respective
technologies instead (Sharrott, 2006).
AFFYMETRIX AND INCYTE
In addition to Affymetrix's litigation with Hyseq, the company also instigated a suit
against Synteni Inc., a company acquired by Incyte. Affymetrix alleged that Incyte
infringed on US 5,445,934, the same patent they asserted against Hyseq. The portion of
the patent that Affymetrix claimed was infringed was for making dense arrays, arrays
containing more than a thousand gene fragments per square centimeter (Service, 1998).
However, Incyte claims that they do not infringe so the suit is unjustified. The
company asserts that since they are using much longer gene fragments than the short
fragments that Affymetrix uses, there is no case for infringement. Furthermore, by
using their own proprietary technology to synthesize the microarrays rather than the
photolithography technique of Affymetrix, it reaffirms that the case has no merit. In
addition, like the case against Hyseq, the litigation with Incyte also continued through a
series of several concurrent lawsuits filed between the two companies over several years.
The Affymetrix versus Incyte litigation represents the intensity and difficulty of being a
major player in the DNA microarray market. After the settlement agreed to by the two
parties, Incyte Genomics decided to refocus its entire corporate strategy and sell off its
microarray division in 2002 to become Incyte Corporation. The company changed its
focus from the synthesis of DNA microarrays to the tools and databases needed to
analyze DNA microarrays. After establishing a business model focus on bioinformatics,
Incyte now uses its technology to help with testing in the pharmaceutical industry. The
knowledge can be used for the development of drugs and conducting test trials of their
efficacy.
From Affymetrix's two major cases with Hyseq and Incyte, it is apparent that that their
patents are strong and allow them to remain dominant in the industry. In its case
against Hyseq, Affymetrix asserted its patents on the GeneChip@ and DNA microarray
density, US 5,445,934 and was able to agree upon a settlement. The company
continued to sue with the same patent against Incyte which suggests that they were
amenable towards the settlement terms they got with Hyseq and were willing to
continue asserting it. On the other hand, Hyseq has not asserted its patents against other
companies showing that they did not get the exact settlement terms they were interested
in the settlement. Since Affymetrix is continually asserting its patents against others
and settling, it means that although their patents do not have the power to stop other
companies but it does have the ability to gain cross-licensing agreements.
AFFYMETRIX AND OXFORD GENE TECHNOLOGY
Affymetrix has also engaged in litigation with Oxford Gene Technology in the United
Kingdom, but it this time the focus of the suit was on the more on the business rather
than the technology. The technology in issue during this case was Oxford Gene
Technology's method for rapidly analyzing genes by analyzing polynucleotide
sequences and an apparatus for synthesizing microarrays. Affymetrix realized the
importance of the patents and entered discussions on licensing the technology from
Oxford Gene Technology. In June 1998, an agreement of $20 million for licensing fess
was agreed upon but right before it was finalized, Affymetrix backed out of the deal.
Instead, to get a license for the technology, Affymetrix bought the company Beckman
Coulter Inc. (a manufacturer of drug delivery systems) which already had a license for
the technology obtained in 1991 (Rouse, 2003). The company was able to make the
purchase for only $10.9 million dollars which in essence allowed them to license the
technology for half the price.
Due to the method that they obtained the license from Oxford Gene Technology,
Oxford Gene Technology filed suit against Affymetrix in 1999. Initially in April 2000,
a trail court ruled that Affymetrix's license to Oxford Gene Technology's patents were
invalid which greatly jeopardized the company's future. Oxford Gene Technology now
had the power to put Affymetrix out of business by refusing a license. However,
Affymetrix appealed the decision and the higher court ruled in favor of Affymetrix.
They determined that there was no wrongdoing on their part in obtaining a legal license
to use the technology for analyzing genes quickly. This case exemplifies the lengths at
which Affymetrix, and in general companies in the industry, will go to survive in the
market. Furthermore, the importance of being able to utilize all the possible technology
out there to be able to develop even more new breakthroughs can be seen.
These three cases represent only a small fraction of the suits that have been filed
between DNA microarray manufacturers. They represent the difficulty of carving out a
substantial share of the DNA microarray market. From past litigation, lessons can be
learned to circumvent potential future litigation. In addition, despite the large amounts
of time and money it takes, companies are still vying for a place in the industry due to
the potential for growth.
BUSINESS STRATEGY
Market
Due to the versatility of DNA microarrays and their potential of unlocking the mysteries
of disease, there is an extremely high demand for the product in the market. However,
there is a significant range in the predictions for their future growth. Some analysts
believe that the entire market of chips and analysis software will experience more than
30% growth per year reach up to $3.6 to $4.5 billion by next year (Bouchie, 2002). In
2004, DNA microarrays were a $700 million market with other analysts projecting a
$200 million a year increase to $1.4 billion in 2010. Despite the promising market, the
current hefty price tag of $500 - $2000 per array limits access of the tool primarily to
research laboratories and universities. In order for the healthcare industry to be able to
use DNA microarrays to diagnose diseases, the price needs to be brought down to $50-
$100 per array. If this price point could be achieved, it is possible that the market could
see an exponential increase in demand.
Although Affymetrix is currently dominant with 80% of the market share due to its high
density DNA microarrays, the future direction of the market could make it difficult for
the company to hold their position. Currently, 75% of the research conducted with
DNA microarrays involved the use of high density arrays, which Affymetrix specializes
in, in order to test a sample across as many polynucleotide probes as possible (Bouchie,
2002). However, once a relatively small number of genes have been associated with a
certain disease, low density arrays can be used to screen those small number of genes
across many patients. Therefore, the demand is currently for high density arrays as
researchers are trying to make connections between genes and diseases first. Once the
associations are made though, the majority of the demand may shift to low density
arrays in a few years (Bouchie, 2002). Although Affymetrix may always dominate the
high density array market, the shift will give companies other than Affymetrix to
capture significant microarray market share in the form of low density arrays.
Not only is the chip side, also known as the "hardware," of the market highly
competitive and tangled in patents, but the "software" side of the actual genes and their
functions is also not without complications since they can also be patented. Then, when
a microarray manufacturer wants to use that sequences for their chip, they must obtain a
license to use that sequence. The problem comes in when the scale and magnitude of
how much information a chip contains is considered. In a single chip, there may be
more than 40,000 different sequences and if each one of those sequences involves a
patented gene, then chip prices will skyrocket and leave manufacturers with little profit.
A problem that could play a larger role in creating a real obstacle to chip development is
if the assignees of the gene patents are unwillingness to license their sequences. For
example, they may only license the sequences to one company exclusively and prevent
competitors from using it or they may not license it at all and attempt to profit from
their innovation themselves. Despite these difficulties those, companies are not
deterred since a lot of competition still remains so that they is not one major leader
dominating the market. In addition, many gene sequences are also in the public domain
and free to any company to use so that they do not have to rely on proprietary ones
(Service, 1998).
Licensing
Due to the intensely dense field of patents in the DNA microarray industry, a business
model focused on protecting the intellectual property of Supramolecular NanoStamping
is a necessity for survival of the technology. Currently, there are two pending patent
applications on the technology that cover the concept of stamping via self-assembly to
gain protection for the technology. To strengthen the impact of the patents, they
encompass the potential for using various initial master types, a variety of substrate
materials and applying the concept to various types of microarrays beyond DNA.
Developing a strong intellectual property portfolio for the technology not only includes
getting patent protection but also includes conducting extensive prior art searching and
patent landscaping to determine the technology space and where it may overlap. By
having a deep and thorough understanding of where Supramolecular NanoStamping fits
into the DNA microarray market, it is possible to anticipate and hopefully avoid any
potential litigation that may occur in the future.
Once patent protection can secured for the technology, it may be implemented into the
market through a licensing strategy. The key point to Supramolecular NanoStamping
technology is its ability to reliably, efficiently and economically reproduce chips from a
master one. Therefore, the technology is crucial for bringing down the cost when
making multiple copies of the same chip, regardless of how the initial chip is made.
This means that any company can apply the method to its own chips since
Supramolecular NanoStamping's underlying concept works independent of the
company's manufacturing process.
To begin with, the first companies that should be targeted for licensing are the major
ones with significant market share, besides Affymetrix. The reason that Affymetrix
would not want to initially be approached is because they currently enjoy the dominant
position in the market and would tend not to want to jeopardize that position by
implementing new technology that hadn't been commercially tested yet. By bringing
the technology to market with say Affymetrix's main competitors, they have the
motivation to take a chance on a technology that would increase their market share and
allow them the possible opportunity to take over Affymetrix's lead. The competitors
would have the opportunity to bring down the cost of their products to a fraction of
what they were before so that demand for their chips would increase because of the low
price. Once the technology can be established and shown to work with one or a few
reputable companies, then the method of driving down costs will want to be
implemented by all companies to remain competitive.
Implementing a licensing strategy rather than a start up strategy will also save on the
cost of developing a start up to commercialized the process. These financial burdens
would be placed on the companies willing to take a chance on the technology. With the
potential to significantly bring down the price on a microarray and proof of concept
showing that it works, it is anticipated that finding a competitive company to invest in
the technology is reasonable and viable. Since the process would require special
machinery in clean-room like conditions, the companies would most likely already have
much of the equipment and means to carry out the process without having to incur the
significant initial costs that a start up would be faced with.
CONCLUSION
DNA microarrays are important tools for sorting through the enormous amount of
information about the human genome. By determining gene expression and conducting
genotyping efficiently, they hold promise for revolutionizing the treatments of diseases
and developments of medicines. Supramolecular NanoStamping is a novel method for
fabricating DNA microarrays to conduct this biological and genetic research. The
process utilizes directed self-assembly to build these devices in an economical method.
It is the first bio-molecule friendly printing technique with high spatial and chemical
information content. Several technical advantages are available by using this method
such as ease of master multiplication, high resolution printing and massive information
transfer. In addition to its technical benefits, Supramolecular NanoStamping also
possesses economic advantages such as fast production times and low costs. Bring this
technology to market will not be without struggle though. Patents will need to be issued
by the United States Patent and Trademark Office and DNA microarray technology will
need to be thoroughly landscaped and search to avoid potential litigation.
Supramolecular NanoStamping is an emerging technology that holds much promise for
changing the DNA microarray industry.
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